Destination Europe

Destination Europe
Severe price erosion and intense competition in the US market has prompted Indian pharma to test European waters by acquisitions, marketing, licensing and tie-ups. Both big and mid-size companies are making a beeline to tap the European opportunity, learns Sapna Dogra.

Talk about India, but invest in China?
The Indian pharmaeutical industry seems set to emerge from the confines of the generics market in which it has largely positioned itself and could soon become a major global player.

Pharma treads the nutra path
Let thy food be thy medicine and thy medicine be thy food. This is what the Father of Medicine, Hippocrates said about the thin line between food and medicine. Looks like the line does not exist anymore as many pharma companies are going the nutra way. Katya Naidu explores

Bangalore gears up for biotech revolution
Katya Naidu reports on Bangalore Bio 2006.

NPIL to acquire Pfizer’s UK facility
Nicholas Piramal India Limited (NPIL) announced its intention to acquire the manufacturing facility of Pfizer, located at Morpeth, Northumberland, UK.

GSK strengthens its Asian presence
GlaxoSmithKline (GSK) is all set to strengthen its presence in Asia with the establishment of its first vaccine manufacturing plant in Singapore.

Biocon to launch new cancer drug
A new cancer drug is on the way from Biocon. An announcement on these lines was made at the inauguration of Biocon Park, India’s largest integrated biotech hub.

Chiron Panacea Vaccines goes IT savvy
SQL Star International has entered into an agreement with Chiron Panacea Vaccines PVT for managing their IT based applications.